bispecific antibodies

2:19
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon
1:21
An update on the state-of-affairs of BiTEs in the world of AML
Marion Subklewe
1:57
An update on AMG-330: can BiTEs be as successful in AML as ALL?
Marion Subklewe
1:21
Bispecific mosunetuzumab shows promise in R/R follicular lymphoma and DLBCL
Ian Flinn
2:03
Bispecific antibody response boosting with ibrutinib for CLL
Adrian Wiestner
1:23
Targeting BCMA with bispecific antibodies in R/R myeloma
Saad Usmani
1:32
Immunotherapeutics against multiple myeloma: it’s all about BCMA
Enrique Ocio
1:35
Monoclonal antibodies: current and future potential
Saad Usmani
2:45
Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
Heinz Ludwig
1:09
Non-hodgkin lymphoma advances in 2018
Steven Rosen
3:29
Novel drugs and targets in MDS
Valeria Santini
6:20
Myeloma 2018 day 2 round-up: CAR T-cell therapy & drug resistance
Florian Bassermann et al.
2:41
Immunotherapy in AML: azacitidine plus checkpoint inhibitors
Naval Daver
1:22
ALL: recent immunotherapeutic developments
Ryan Cassaday
1:27
CAR T-cells in ALL: an overview
Oliver Ottmann
2:22
New strategies for durable remission in MM
Niels van de Donk
The content of VJHemOnc is intended for healthcare professionals